Neuroblastoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan and Melphalan Variant #01 | — | R 5 233 | — | — | — | — | — | 1 |
GM-CSF, IL-2, Isotretinoin, Dinutuximab Variant not yet assigned - COG protocol Partial | — | R 4 612 | 28d | — | — | — | — | — |
Isotretinoin monotherapy Variant #01 | — | R 1 942 | 28d | — | — | — | — | — |
Isotretinoin and Dinutuximab beta Variant #01 Partial | — | R 1 942 | 35d | — | — | — | — | — |
Observation Partial | — | — | — | ~10.3 mo | ~37.1 mo | — | — | 65 |
5 of 5 regimens shown